Literature DB >> 9021762

Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme.

J R McDermott1, A M Gibson.   

Abstract

We examined the degradation of Alzheimer's beta-amyloid protein (1-40) by soluble and synaptic membrane fractions from post mortem human and fresh rat brain using HPLC. Most of the activity at neutral pH was in the soluble fraction. The activity was thiol and metal dependent, with a similar inhibition profile to insulin-degrading enzyme. Immunoprecipitation of insulin-degrading enzyme from the human soluble fraction using a monoclonal antibody removed over 85% of the beta-amyloid protein degrading activity. Thus insulin-degrading enzyme is the main soluble beta-amyloid degrading enzyme at neutral pH in human brain. The highest beta-amyloid protein degrading activity in the soluble fractions occurred between pH 4-5, and this activity was inhibited by pepstatin, implicating an aspartyl protease. Synaptic membranes had much lower beta-amyloid protein degrading activity than the soluble fraction. EDTA (2mM) caused over 85% inhibition of the degrading activity but inhibitors of endopeptidases -24.11, -24.15, -24.16, angiotensin converting enzyme, aminopeptidases, and carboxypeptidases had little or no effect.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9021762     DOI: 10.1023/a:1027325304203

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  44 in total

1.  Endopeptidase-24.11: a cell-surface enzyme for metabolizing regulatory peptides.

Authors:  A J Kenny; M A Bowes; N S Gee; R Matsas
Journal:  Biochem Soc Trans       Date:  1985-04       Impact factor: 5.407

2.  Insulin processing by the liver.

Authors:  J F Caro; G Muller; J A Glennon
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

3.  Insulin-degrading enzyme: stable expression of the human complementary DNA, characterization of its protein product, and chromosomal mapping of the human and mouse genes.

Authors:  J A Affholter; C L Hsieh; U Francke; R A Roth
Journal:  Mol Endocrinol       Date:  1990-08

4.  Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system.

Authors:  A M Cataldo; J L Barnett; S A Berman; J Li; S Quarless; S Bursztajn; C Lippa; R A Nixon
Journal:  Neuron       Date:  1995-03       Impact factor: 17.173

5.  Isolation of insulin degradation products from endosomes derived from intact rat liver.

Authors:  F G Hamel; B I Posner; J J Bergeron; B H Frank; W C Duckworth
Journal:  J Biol Chem       Date:  1988-05-15       Impact factor: 5.157

6.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing.

Authors:  M Shoji; T E Golde; J Ghiso; T T Cheung; S Estus; L M Shaffer; X D Cai; D M McKay; R Tintner; B Frangione
Journal:  Science       Date:  1992-10-02       Impact factor: 47.728

7.  Hydrolysis of amyloid precursor protein-derived peptides by cysteine proteinases and extracts of rat brain clathrin-coated vesicles.

Authors:  N Marks; M J Berg; L M Chi; J Choi; R Durrie; J Swistok; R C Makofske; W Danho; V S Sapirstein
Journal:  Peptides       Date:  1994-01       Impact factor: 3.750

8.  The rat insulin-degrading enzyme. Molecular cloning and characterization of tissue-specific transcripts.

Authors:  H Baumeister; D Müller; M Rehbein; D Richter
Journal:  FEBS Lett       Date:  1993-02-15       Impact factor: 4.124

9.  beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms.

Authors:  C Haass; A Y Hung; M G Schlossmacher; D B Teplow; D J Selkoe
Journal:  J Biol Chem       Date:  1993-02-15       Impact factor: 5.157

10.  Rat kidney endopeptidase 24.16. Purification, physico-chemical characteristics and differential specificity towards opiates, tachykinins and neurotensin-related peptides.

Authors:  H Barelli; J P Vincent; F Checler
Journal:  Eur J Biochem       Date:  1993-01-15
View more
  44 in total

1.  Purified recombinant insulin-degrading enzyme degrades amyloid beta-protein but does not promote its oligomerization.

Authors:  V Chesneau; K Vekrellis; M R Rosner; D J Selkoe
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 2.  The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  G Stennis Watson; Suzanne Craft
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

3.  A common genetic system for functional studies of pitrilysin and related M16A proteases.

Authors:  Benjamin J Alper; Tatyana E Nienow; Walter K Schmidt
Journal:  Biochem J       Date:  2006-08-15       Impact factor: 3.857

4.  Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.

Authors:  Benjamin J Alper; Jarrad W Rowse; Walter K Schmidt
Journal:  Yeast       Date:  2009-11       Impact factor: 3.239

5.  Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.

Authors:  A Mukherjee; E Song; M Kihiko-Ehmann; J P Goodman; J S Pyrek; S Estus; L B Hersh
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

Review 6.  Alois Alzheimer revisited: differences in origin of the disease carrying his name.

Authors:  K Maurer; S Hoyer
Journal:  J Neural Transm (Vienna)       Date:  2006-10-23       Impact factor: 3.575

7.  A capillary electrophoresis method for evaluation of Abeta proteolysis in vitro.

Authors:  Benjamin J Alper; Walter K Schmidt
Journal:  J Neurosci Methods       Date:  2008-11-21       Impact factor: 2.390

Review 8.  Insulin resistance and Alzheimer's disease.

Authors:  Suzanne M de la Monte
Journal:  BMB Rep       Date:  2009-08-31       Impact factor: 4.778

Review 9.  General anesthetics and β-amyloid protein.

Authors:  Zhongcong Xie; Zhipeng Xu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-08-14       Impact factor: 5.067

10.  Involvement of insulin-degrading enzyme in the clearance of beta-amyloid at the blood-CSF barrier: Consequences of lead exposure.

Authors:  Mamta Behl; Yanshu Zhang; Wei Zheng
Journal:  Cerebrospinal Fluid Res       Date:  2009-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.